Item 5.02. Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On May 20, 2020, at the 2020 Annual Meeting of Stockholders (the Annual Meeting)
of Exelixis, Inc. (Exelixis), Exelixis' stockholders approved the amendment and
restatement of the Exelixis, Inc. 2017 Equity Incentive Plan (as so amended and
restated, the 2017 Plan). The 2017 Plan became effective immediately upon
stockholder approval at the Annual Meeting.
The amendment and restatement was effected primarily: (a) to increase the share
reserve under the 2017 Plan by 21,000,000 shares, subject to adjustment for
certain changes in the capitalization of Exelixis; and (b) to specify that
(i) the provision providing for accelerated vesting of outstanding awards in the
event of certain corporate transactions involving Exelixis in which the
surviving or acquiring corporation (or its parent company) does not assume,
continue or substitute for such awards will also apply to a change in control of
Exelixis and (ii) for purposes of any such acceleration provided by such
provision, as well as the provisions providing for accelerated vesting of
outstanding awards in the event of certain change in control acquisitions
involving Exelixis that are not approved by the Board of Directors of Exelixis
(the Board) or the Compensation Committee of the Board, and certain involuntary
terminations of service that occur within one month before, as of, or within 13
months after a change in control of Exelixis, with respect to any such awards
that are subject to performance-based vesting conditions or requirements,
vesting will be deemed to be satisfied at the target level of performance.
The terms of the 2017 Plan provide for the grant of incentive stock options,
nonstatutory stock options, stock appreciation rights, restricted stock awards,
restricted stock unit awards, other stock awards, and performance awards that
may be settled in cash, stock, or other property. Subject to adjustment for
certain changes in the capitalization of Exelixis, the aggregate number of
shares of Exelixis' common stock that may be issued under the 2017 Plan will not
exceed 45,453,064 shares (plus the Prior Plans' Returning Shares, as such shares
become available from time to time).  The "Prior Plans' Returning Shares" are
shares subject to outstanding stock awards granted under specified Exelixis
prior plans, in each case that, from and after May 24, 2017, (i) expire or
terminate for any reason prior to exercise or settlement, (ii) are forfeited,
cancelled or otherwise returned to Exelixis because of the failure to meet a
contingency or condition required for the vesting of such shares, or (iii) other
than with respect to outstanding appreciation awards (as defined below) granted
under such prior plans, are reacquired or withheld (or not issued) by Exelixis
to satisfy a tax withholding obligation in connection with a stock award.
The number of shares of Exelixis' common stock available for issuance under the
2017 Plan will be reduced by (i) one share for each share of common stock issued
pursuant to a stock option or stock appreciation right with an exercise or
strike price of at least 100% of the fair market value of the underlying common
stock on the date of grant (an "appreciation award") granted under the 2017
Plan, and (ii) 1.5 shares for each share of common stock issued pursuant to a
full value award (i.e., any stock award that is not an appreciation award)
granted under the 2017 Plan.
A more complete summary of the terms of the 2017 Plan is set forth in Exelixis'
definitive proxy statement for the Annual Meeting filed with the Securities and
Exchange Commission on April 9, 2020 (the Proxy Statement). That summary and the
foregoing description are qualified in their entirety by reference to the text
of the 2017 Plan, which is filed as Appendix A to the Proxy Statement.
Item 5.07. Submission of Matters to a Vote of Security Holders.
Exelixis held the Annual Meeting on May 20, 2020 via live webcast. At the Annual
Meeting, the Exelixis stockholders were asked to vote upon:
1.     The election of each of eleven directors to hold office until the next
       annual meeting of stockholders in 2021. The nominees for election to these
       positions were Charles Cohen, Ph.D., Carl B. Feldbaum, Esq., Maria C.
       Freire, Ph.D., Alan M. Garber, M.D., Ph.D., Vincent T. Marchesi, M.D.,
       Ph.D., Michael M. Morrissey, Ph.D., Stelios Papadopoulos, Ph.D., George
       Poste, DVM, Ph.D., FRS, Julie Anne Smith, Lance Willsey, M.D. and Jack L.
       Wyszomierksi;


2.     The ratification of the selection by the Audit Committee of the Board of
       Directors of Ernst & Young LLP as Exelixis' independent registered public
       accounting firm for the fiscal year ending January 1, 2021;

--------------------------------------------------------------------------------




3.     The approval of the 2017 Plan to, among other things, increase the number
       of shares authorized for issuance by 21,000,000 shares; and


4.     The approval, on an advisory basis, of the compensation of Exelixis' named
       executive officers, as disclosed in the Proxy Statement.


The voting results of the matters presented at the Annual Meeting are as
follows:
1.     The election of each of Charles Cohen, Ph.D., Carl B. Feldbaum, Esq.,
       Maria C. Freire, Ph.D., Alan M. Garber, M.D., Ph.D., Vincent T. Marchesi,
       M.D., Ph.D., Michael M. Morrissey, Ph.D., Stelios Papadopoulos, Ph.D.,
       George Poste, DVM, Ph.D., FRS, Julie Anne Smith, Lance Willsey, M.D. and
       Jack L. Wyszomierksi as directors of Exelixis until the next annual
       meeting of stockholders in 2021, and until his or her successor is elected
       and qualified, or until his or her earlier death, resignation or removal,
       was approved as follows:


                                                                          BROKER
                                     FOR        AGAINST      ABSTAIN    NON-VOTES
Charles Cohen, Ph.D.             200,935,765   15,986,323     515,466   42,605,432
Carl B. Feldbaum, Esq.           210,012,568    6,792,156     632,830   42,605,432
Maria C. Freire, Ph.D.           214,133,234    2,764,274     540,046   42,605,432
Alan M. Garber, M.D., Ph.D.      195,430,158   21,446,555     560,841   42,605,432
Vincent T. Marchesi, M.D., Ph.D. 201,278,034   15,602,949     556,571   42,605,432
Michael M. Morrissey, Ph.D.      214,582,844    2,397,409     457,301   42,605,432
Stelios Papadopoulos, Ph.D.      195,744,824   19,338,654   2,354,076   42,605,432
George Poste, DVM, Ph.D., FRS    212,327,201    4,508,786     601,567   42,605,432
Julie Anne Smith                 215,757,078    1,050,705     629,771   42,605,432
Lance Willsey, M.D.              201,321,357   15,569,811     546,386   42,605,432
Jack L. Wyszomierksi             208,099,076    8,569,066     769,412   42,605,432


2.     The ratification of Ernst & Young LLP as Exelixis' independent registered
       public accounting firm for the fiscal year ending January 1, 2021, was
       approved as follows:


                                     BROKER
    FOR        AGAINST    ABSTAIN   NON-VOTES
256,694,941   2,680,278   667,767           0


3.     The approval of the 2017 Plan to, among other things, increase the number
       of shares authorized for issuance by 21,000,000 shares, was approved as
       follows:


                                         BROKER
    FOR        AGAINST      ABSTAIN    NON-VOTES
200,703,043   15,336,567   1,397,944   42,605,432


4.     The compensation of Exelixis' named executive officers, as disclosed in
       the Proxy Statement, received advisory approval as follows:


                                      BROKER
    FOR        AGAINST    ABSTAIN   NON-VOTES
211,852,587   4,786,316   798,651   42,605,432

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses